Prohászka Z, Duba J, Horváth L, Császár A, Karádi I, Szebeni A, Singh M, Fekete B, Romics L, Füst G
Semmelweis University, Budapest, Hungary.
Eur J Clin Invest. 2001 Apr;31(4):285-92. doi: 10.1046/j.1365-2362.2001.00819.x.
Recent observations indicate an association between antibodies against mycobacterial heat shock protein (hsp65) and coronary heart disease (CHD). Previously, we reported on marked differences in antigen specificity and complement activating ability of anti-hsp65 antibodies and auto-antibodies against human heat shock protein, hsp60. Here, we investigated whether there are differences between antih-sp65 and anti-hsp60 antibodies in their association with CHD.
We measured by ELISA the levels of antibodies to hsp65, hsp60 and E. coli-derived GroEL in three groups: Group I, 357 patients with severe CHD who underwent by-pass surgery; Group II, 67 patients with negative coronary angiography; Group III, 321 healthy blood donors. Antibodies against Helicobacter pylori were also measured by commercial ELISA.
As calculated by multiple regression analysis, the levels of anti-hsp60 auto-antibodies were significantly higher in Group I compared to Group II (P = 0.007) or Group III (P < 0.0001). By contrast, although concentrations of anti-hsp65 and anti-GroEL antibodies in Group I were higher than in Group III, no significant differences between Group I and Group II were found. Antibodies to the two bacterial hsp strongly correlated to each other, but either did not correlate or weakly correlated to hsp60. In Group I, serum concentrations of anti-H.pylori antibodies significantly correlated with those of anti-hsp65 and anti-GroEL antibodies but they did not correlate with the anti-hsp60 antibodies.
As to their clinical relevance, a remarkable difference become evident between antibodies to human hsp60 and antibodies against bacterial hsp in the extent of association with CHD. On the basis of these findings and some pertinent literature data, an alternative explanation for the association between high level of anti-hsp antibodies and atherosclerotic vascular diseases is raised.
最近的观察表明,抗分枝杆菌热休克蛋白(hsp65)抗体与冠心病(CHD)之间存在关联。此前,我们报道了抗hsp65抗体和抗人热休克蛋白hsp60自身抗体在抗原特异性和补体激活能力方面存在显著差异。在此,我们研究了抗hsp65和抗hsp60抗体与冠心病的关联是否存在差异。
我们通过酶联免疫吸附测定(ELISA)测量了三组中抗hsp65、hsp60和大肠杆菌来源的GroEL抗体的水平:第一组,357例接受搭桥手术的严重冠心病患者;第二组,67例冠状动脉造影阴性的患者;第三组,321名健康献血者。还通过商用ELISA测量了抗幽门螺杆菌抗体。
通过多元回归分析计算,与第二组(P = 0.007)或第三组(P < 0.0001)相比,第一组中抗hsp60自身抗体水平显著更高。相比之下,虽然第一组中抗hsp65和抗GroEL抗体的浓度高于第三组,但未发现第一组和第二组之间存在显著差异。两种细菌热休克蛋白的抗体彼此强烈相关,但与hsp60要么不相关,要么弱相关。在第一组中,抗幽门螺杆菌抗体的血清浓度与抗hsp65和抗GroEL抗体的血清浓度显著相关,但与抗hsp60抗体不相关。
就其临床相关性而言,人hsp60抗体与细菌热休克蛋白抗体在与冠心病的关联程度上存在明显差异。基于这些发现和一些相关文献数据,我们对高水平抗热休克蛋白抗体与动脉粥样硬化性血管疾病之间的关联提出了另一种解释。